{
    "xml": "<topic id=\"PHP1869\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/fluticasone\" basename=\"fluticasone\" title=\"FLUTICASONE\">\n<title>FLUTICASONE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_497\" namespace=\"/interactions/list-of-drug-interactions/corticosteroids/fluticasone\">Fluticasone</xref>\n</p>\n<data name=\"vtmid\">108632003</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_832374428\" title=\"Corticosteroids\">Corticosteroids</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34550\" title=\"CORTICOSTEROIDS (TOPICAL)\" namespace=\"/drug-classes/corticosteroids-topical\">CORTICOSTEROIDS (TOPICAL)</xref>\n</data>\r\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34648\" title=\"CORTICOSTEROIDS (INTRANASAL)\" namespace=\"/drug-classes/corticosteroids-intranasal\">CORTICOSTEROIDS (INTRANASAL)</xref>\n</data>\r\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34650\" title=\"CORTICOSTEROIDS (INHALED)\" namespace=\"/drug-classes/corticosteroids-inhaled\">CORTICOSTEROIDS (INHALED)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">   </data>\r\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP63730\" outputclass=\"indicationsAndDose\" rev=\"1.42\" parent=\"/drugs/fluticasone\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of asthma</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By inhalation of powder</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 5&#8211;15 years</p>\n<p>Initially 50&#8211;100&#8239;micrograms twice daily (max. per dose 200&#8239;micrograms twice daily), dose to be adjusted as necessary.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>Initially 100&#8211;500&#8239;micrograms twice daily (max. per dose 1&#8239;mg twice daily), dose may be increased according to severity of asthma. Doses above 500&#8239;micrograms twice daily initiated by a specialist.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 100&#8211;500&#8239;micrograms twice daily (max. per dose 1&#8239;mg twice daily), dose may be increased according to severity of asthma. Doses above 500&#8239;micrograms twice daily initiated by a specialist.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By inhalation of aerosol</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 4&#8211;15 years</p>\n<p>Initially 50&#8211;100&#8239;micrograms twice daily (max. per dose 200&#8239;micrograms twice daily), dose to be adjusted as necessary.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>Initially 100&#8211;500&#8239;micrograms twice daily (max. per dose 1&#8239;mg twice daily), dose may be increased according to severity of asthma. Doses above 500&#8239;micrograms twice daily initiated by a specialist.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 100&#8211;500&#8239;micrograms twice daily (max. per dose 1&#8239;mg twice daily), dose may be increased according to severity of asthma. Doses above 500&#8239;micrograms twice daily initiated by a specialist.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By inhalation of nebulised suspension</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 4&#8211;15 years</p>\n<p>1&#8239;mg twice daily.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>0.5&#8211;2&#8239;mg twice daily.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.5&#8211;2&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis and treatment of allergic rhinitis and perennial rhinitis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intranasal administration using nasal spray</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 4&#8211;11 years</p>\n<p>50&#8239;micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 50&#8239;micrograms twice daily.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>100&#8239;micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 100&#8239;micrograms twice daily; reduced to 50&#8239;micrograms once daily, dose to be administered into each nostril, dose to be reduced when control achieved.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>100&#8239;micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 100&#8239;micrograms twice daily; reduced to 50&#8239;micrograms once daily, dose to be administered into each nostril, dose to be reduced when control achieved.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Nasal polyps</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intranasal administration using nasal drops</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 16&#8211;17 years</p>\n<p>200&#8239;micrograms 1&#8211;2 times a day, to be administered into each nostril, dose of 200&#8239;micrograms approximately 6 drops, alternative treatment should be considered if no improvement after 4&#8211;6 weeks.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>200&#8239;micrograms 1&#8211;2 times a day, to be administered into each nostril, dose of 200&#8239;micrograms approximately 6 drops, alternative treatment should be considered if no improvement after 4&#8211;6 weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe inflammatory skin disorders such as dermatitis and eczemas unresponsive to less potent corticosteroids</p>\n<p outputclass=\"therapeuticIndication\">Psoriasis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">To the skin</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 3 months&#8211;17 years</p>\n<p>Apply 1&#8211;2 times a day, to be applied thinly.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Apply 1&#8211;2 times a day, to be applied thinly.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"potency\">\n<title>Potency</title>\n<p>Fluticasone cream 0.05%: potent.</p>\n<p>Fluticasone ointment 0.005%: potent.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63580\" outputclass=\"unlicensedUse\" rev=\"1.8\" parent=\"/drugs/fluticasone\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">topical</ph> use in children</p>\n<p>Not licensed for use in children under 3 months.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63617\" outputclass=\"sideEffects\" rev=\"1.19\" parent=\"/drugs/fluticasone\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"specificSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">When used by inhalation</p>\n<p>\n<ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Nasal ulceration</p>\n<p>Nasal ulceration occurs commonly with nasal preparations containing fluticasone furoate.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63809\" outputclass=\"directionsForAdministration\" rev=\"1.15\" parent=\"/drugs/fluticasone\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\n</p>\n<p>Fluticasone nebuliser liquid may be diluted with sterile sodium chloride 0.9%. It is not suitable for use in ultrasonic nebulisers.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63658\" outputclass=\"patientAndCarerAdvice\" rev=\"1.28\" parent=\"/drugs/fluticasone\">\n<title>Patient and carer advice</title>\n<body>\r\n\r\n\r\n<section outputclass=\"patientResources\">\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\r\n</p>\r\n<p>With high doses, a steroid card should be supplied.</p>\n</sectiondiv>\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">In children</p>\r\n<p outputclass=\"title\">Medicines for Children leaflet: Fluticasone inhaler for asthma prevention (prophylaxis)</p>\r\n<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/fluticasone-inhaler-for-asthma-prevention\">www.medicinesforchildren.org.uk/fluticasone-inhaler-for-asthma-prevention</xref>\n</p>\n</sectiondiv>\n</section>\r\n<section outputclass=\"generalPatientAdvice\">\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph>\r\n</p>\r\n<p>Patients or carers should be given advice on how to administer all fluticasone inhalations preparations.</p>\n</sectiondiv>\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">topical</ph> use</p>\r\n<p>Patients or carers should be given advice on application of fluticasone creams and ointments,</p>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP63530\" outputclass=\"nationalFunding\" rev=\"1.9\" parent=\"/drugs/fluticasone\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph> in adults</p>\n<p>The <i>Scottish Medicines Consortium</i> has advised (March 2014) that fluticasone furoate/vilanterol (<i>Relvar Ellipta</i>\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland in patients with severe chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV<sub>1</sub>) less than 50% of the predicted normal value.</p>\n</sectiondiv>\n</sectiondiv>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph> in adults</p>\n<p>The <i>Scottish Medicines Consortium</i> has advised (March 2014) that <i>Seretide 500 Accuhaler</i>\n<tm tmtype=\"reg\"/> is <b>not</b> recommended for restricted use within NHS Scotland for chronic obstructive pulmonary disease in patients with a forced expiratory volume in 1 second (FEV<sub>1</sub>) less than 60% and greater than 50% of the predicted normal value, with significant symptoms despite regular bronchodilator therapy, and a history of repeated exacerbations.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP63506\" outputclass=\"exceptionsToLegalCategory\" rev=\"1.10\" parent=\"/drugs/fluticasone\">\n<title>Exceptions to legal category</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intranasal</ph> use in adults</p>\n<p>Preparations of fluticasone propionate can be sold to the public for nasal administration (other than by pressurised nasal spray) if supplied for the prevention and treatment of allergic rhinitis in adults over 18 years, subject to max. single dose of 100&#8239;micrograms per nostril, max. daily dose of 200&#8239;micrograms per nostril for max. 3 months, and a pack size of 3&#8239;mg.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1869-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/fluticasone\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76192\" title=\"Pressurised inhalation\" namespace=\"/drugs/fluticasone/pressurised-inhalation\">Pressurised inhalation</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76157\" title=\"Inhalation powder\" namespace=\"/drugs/fluticasone/inhalation-powder\">Inhalation powder</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76163\" title=\"Nebuliser liquid\" namespace=\"/drugs/fluticasone/nebuliser-liquid\">Nebuliser liquid</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76150\" title=\"Cream\" namespace=\"/drugs/fluticasone/cream\">Cream</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76170\" title=\"Ointment\" namespace=\"/drugs/fluticasone/ointment\">Ointment</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76199\" title=\"Spray\" namespace=\"/drugs/fluticasone/spray\">Spray</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76184\" title=\"Nasal drops\" namespace=\"/drugs/fluticasone/nasal-drops\">Nasal drops</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85605\" namespace=\"/drugs/fluticasone-with-formoterol\" title=\"FLUTICASONE WITH FORMOTEROL\" count=\"1\" rel=\"backlink\">FLUTICASONE WITH FORMOTEROL</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85606\" namespace=\"/drugs/fluticasone-with-salmeterol\" title=\"FLUTICASONE WITH SALMETEROL\" count=\"1\" rel=\"backlink\">FLUTICASONE WITH SALMETEROL</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85607\" namespace=\"/drugs/fluticasone-with-vilanterol\" title=\"FLUTICASONE WITH VILANTEROL\" count=\"1\" rel=\"backlink\">FLUTICASONE WITH VILANTEROL</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP88022\" namespace=\"/drugs/azelastine-with-fluticasone\" title=\"AZELASTINE WITH FLUTICASONE\" count=\"1\" rel=\"backlink\">AZELASTINE WITH FLUTICASONE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78318\" namespace=\"/treatment-summaries/airways-disease-use-of-corticosteroids\" title=\"Airways disease, use of corticosteroids\" count=\"1\" rel=\"backlink\">Airways disease, use of corticosteroids</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78495\" namespace=\"/treatment-summaries/nose\" title=\"Nose\" count=\"1\" rel=\"backlink\">Nose</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_497\" namespace=\"/interactions/list-of-drug-interactions/corticosteroids/fluticasone\" title=\"Fluticasone\" count=\"1\" rel=\"link\">Fluticasone</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34550\" namespace=\"/drug-classes/corticosteroids-topical\" title=\"CORTICOSTEROIDS (TOPICAL)\" count=\"1\" rel=\"link\">CORTICOSTEROIDS (TOPICAL)</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34648\" namespace=\"/drug-classes/corticosteroids-intranasal\" title=\"CORTICOSTEROIDS (INTRANASAL)\" count=\"1\" rel=\"link\">CORTICOSTEROIDS (INTRANASAL)</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34650\" namespace=\"/drug-classes/corticosteroids-inhaled\" title=\"CORTICOSTEROIDS (INHALED)\" count=\"1\" rel=\"link\">CORTICOSTEROIDS (INHALED)</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76192\" namespace=\"/drugs/fluticasone/pressurised-inhalation\" title=\"Pressurised inhalation\" count=\"1\" rel=\"link\">Pressurised inhalation</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76157\" namespace=\"/drugs/fluticasone/inhalation-powder\" title=\"Inhalation powder\" count=\"1\" rel=\"link\">Inhalation powder</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76163\" namespace=\"/drugs/fluticasone/nebuliser-liquid\" title=\"Nebuliser liquid\" count=\"1\" rel=\"link\">Nebuliser liquid</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76150\" namespace=\"/drugs/fluticasone/cream\" title=\"Cream\" count=\"1\" rel=\"link\">Cream</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76170\" namespace=\"/drugs/fluticasone/ointment\" title=\"Ointment\" count=\"1\" rel=\"link\">Ointment</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76199\" namespace=\"/drugs/fluticasone/spray\" title=\"Spray\" count=\"1\" rel=\"link\">Spray</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76184\" namespace=\"/drugs/fluticasone/nasal-drops\" title=\"Nasal drops\" count=\"1\" rel=\"link\">Nasal drops</xref>\n</links>\n</topic>",
    "id": "PHP1869",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/fluticasone",
    "basename": "fluticasone",
    "title": "FLUTICASONE",
    "interactants": [
        {
            "id": "bnf_int_497",
            "label": "Fluticasone"
        }
    ],
    "vtmid": "108632003",
    "drugClassification": [
        "Corticosteroids"
    ],
    "inheritsFromClass": [
        "CORTICOSTEROIDS (TOPICAL)",
        "CORTICOSTEROIDS (INTRANASAL)",
        "CORTICOSTEROIDS (INHALED)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of asthma",
                        "html": "Prophylaxis of asthma"
                    }
                ],
                "specificity": {
                    "routes": [
                        "inhalation of nebulised suspension"
                    ],
                    "textContent": "By inhalation of nebulised suspension",
                    "html": "By inhalation of nebulised suspension"
                },
                "child": [
                    {
                        "textContent": "Initially 50&#8211;100 micrograms twice daily (max. per dose 200 micrograms twice daily), dose to be adjusted as necessary.",
                        "html": "<p>Initially 50&#8211;100&#8239;micrograms twice daily (max. per dose 200&#8239;micrograms twice daily), dose to be adjusted as necessary.</p>",
                        "ageGroup": "5&#8211;15 years"
                    },
                    {
                        "textContent": "Initially 100&#8211;500 micrograms twice daily (max. per dose 1 mg twice daily), dose may be increased according to severity of asthma. Doses above 500 micrograms twice daily initiated by a specialist.",
                        "html": "<p>Initially 100&#8211;500&#8239;micrograms twice daily (max. per dose 1&#8239;mg twice daily), dose may be increased according to severity of asthma. Doses above 500&#8239;micrograms twice daily initiated by a specialist.</p>",
                        "ageGroup": "16&#8211;17 years"
                    },
                    {
                        "textContent": "Initially 50&#8211;100 micrograms twice daily (max. per dose 200 micrograms twice daily), dose to be adjusted as necessary.",
                        "html": "<p>Initially 50&#8211;100&#8239;micrograms twice daily (max. per dose 200&#8239;micrograms twice daily), dose to be adjusted as necessary.</p>",
                        "ageGroup": "4&#8211;15 years"
                    },
                    {
                        "textContent": "Initially 100&#8211;500 micrograms twice daily (max. per dose 1 mg twice daily), dose may be increased according to severity of asthma. Doses above 500 micrograms twice daily initiated by a specialist.",
                        "html": "<p>Initially 100&#8211;500&#8239;micrograms twice daily (max. per dose 1&#8239;mg twice daily), dose may be increased according to severity of asthma. Doses above 500&#8239;micrograms twice daily initiated by a specialist.</p>",
                        "ageGroup": "16&#8211;17 years"
                    },
                    {
                        "textContent": "1 mg twice daily.",
                        "html": "<p>1&#8239;mg twice daily.</p>",
                        "ageGroup": "4&#8211;15 years"
                    },
                    {
                        "textContent": "0.5&#8211;2 mg twice daily.",
                        "html": "<p>0.5&#8211;2&#8239;mg twice daily.</p>",
                        "ageGroup": "16&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 100&#8211;500 micrograms twice daily (max. per dose 1 mg twice daily), dose may be increased according to severity of asthma. Doses above 500 micrograms twice daily initiated by a specialist.",
                        "html": "<p>Initially 100&#8211;500&#8239;micrograms twice daily (max. per dose 1&#8239;mg twice daily), dose may be increased according to severity of asthma. Doses above 500&#8239;micrograms twice daily initiated by a specialist.</p>"
                    },
                    {
                        "textContent": "Initially 100&#8211;500 micrograms twice daily (max. per dose 1 mg twice daily), dose may be increased according to severity of asthma. Doses above 500 micrograms twice daily initiated by a specialist.",
                        "html": "<p>Initially 100&#8211;500&#8239;micrograms twice daily (max. per dose 1&#8239;mg twice daily), dose may be increased according to severity of asthma. Doses above 500&#8239;micrograms twice daily initiated by a specialist.</p>"
                    },
                    {
                        "textContent": "0.5&#8211;2 mg twice daily.",
                        "html": "<p>0.5&#8211;2&#8239;mg twice daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis and treatment of allergic rhinitis and perennial rhinitis",
                        "html": "Prophylaxis and treatment of allergic rhinitis and perennial rhinitis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intranasal administration using nasal spray"
                    ],
                    "textContent": "By intranasal administration using nasal spray",
                    "html": "By intranasal administration using nasal spray"
                },
                "child": [
                    {
                        "textContent": "50 micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 50 micrograms twice daily.",
                        "html": "<p>50&#8239;micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 50&#8239;micrograms twice daily.</p>",
                        "ageGroup": "4&#8211;11 years"
                    },
                    {
                        "textContent": "100 micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 100 micrograms twice daily; reduced to 50 micrograms once daily, dose to be administered into each nostril, dose to be reduced when control achieved.",
                        "html": "<p>100&#8239;micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 100&#8239;micrograms twice daily; reduced to 50&#8239;micrograms once daily, dose to be administered into each nostril, dose to be reduced when control achieved.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "100 micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 100 micrograms twice daily; reduced to 50 micrograms once daily, dose to be administered into each nostril, dose to be reduced when control achieved.",
                        "html": "<p>100&#8239;micrograms once daily, to be administered into each nostril preferably in the morning, increased if necessary to 100&#8239;micrograms twice daily; reduced to 50&#8239;micrograms once daily, dose to be administered into each nostril, dose to be reduced when control achieved.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Nasal polyps",
                        "html": "Nasal polyps"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intranasal administration using nasal drops"
                    ],
                    "textContent": "By intranasal administration using nasal drops",
                    "html": "By intranasal administration using nasal drops"
                },
                "child": [
                    {
                        "textContent": "200 micrograms 1&#8211;2 times a day, to be administered into each nostril, dose of 200 micrograms approximately 6 drops, alternative treatment should be considered if no improvement after 4&#8211;6 weeks.",
                        "html": "<p>200&#8239;micrograms 1&#8211;2 times a day, to be administered into each nostril, dose of 200&#8239;micrograms approximately 6 drops, alternative treatment should be considered if no improvement after 4&#8211;6 weeks.</p>",
                        "ageGroup": "16&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "200 micrograms 1&#8211;2 times a day, to be administered into each nostril, dose of 200 micrograms approximately 6 drops, alternative treatment should be considered if no improvement after 4&#8211;6 weeks.",
                        "html": "<p>200&#8239;micrograms 1&#8211;2 times a day, to be administered into each nostril, dose of 200&#8239;micrograms approximately 6 drops, alternative treatment should be considered if no improvement after 4&#8211;6 weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe inflammatory skin disorders such as dermatitis and eczemas unresponsive to less potent corticosteroids",
                        "html": "Severe inflammatory skin disorders such as dermatitis and eczemas unresponsive to less potent corticosteroids"
                    },
                    {
                        "textContent": "Psoriasis",
                        "html": "Psoriasis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "To the skin"
                    ],
                    "textContent": "To the skin",
                    "html": "To the skin"
                },
                "child": [
                    {
                        "textContent": "Apply 1&#8211;2 times a day, to be applied thinly.",
                        "html": "<p>Apply 1&#8211;2 times a day, to be applied thinly.</p>",
                        "ageGroup": "3 months&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Apply 1&#8211;2 times a day, to be applied thinly.",
                        "html": "<p>Apply 1&#8211;2 times a day, to be applied thinly.</p>"
                    }
                ]
            }
        ],
        "potency": [
            {
                "type": "potency",
                "title": "Potency",
                "textContent": "Fluticasone cream 0.05%: potent.\n\nFluticasone ointment 0.005%: potent.",
                "html": "<p>Fluticasone cream 0.05%: potent.</p><p>Fluticasone ointment 0.005%: potent.</p>"
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "specificity": {
                    "textContent": "With topical use in children",
                    "html": "With <ph outputclass=\"route\">topical</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "topical"
                    ]
                },
                "textContent": "Not licensed for use in children under 3 months.",
                "html": "<p>Not licensed for use in children under 3 months.</p>"
            }
        ]
    },
    "sideEffects": {
        "specific": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    },
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "When used by inhalation",
                            "html": "When used by inhalation",
                            "routes": [
                                "inhalation"
                            ]
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Nasal ulceration",
                "textContent": "Nasal ulceration occurs commonly with nasal preparations containing fluticasone furoate.",
                "html": "<p>Nasal ulceration occurs commonly with nasal preparations containing fluticasone furoate.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "Fluticasone nebuliser liquid may be diluted with sterile sodium chloride 0.9%. It is not suitable for use in ultrasonic nebulisers.",
                "html": "<p>Fluticasone nebuliser liquid may be diluted with sterile sodium chloride 0.9%. It is not suitable for use in ultrasonic nebulisers.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "With high doses, a steroid card should be supplied.",
                "html": "<p>With high doses, a steroid card should be supplied.</p>"
            },
            {
                "type": "patientResources",
                "references": [
                    {
                        "id": "http://www.medicinesforchildren.org.uk/fluticasone-inhaler-for-asthma-prevention",
                        "label": "www.medicinesforchildren.org.uk/fluticasone-inhaler-for-asthma-prevention"
                    }
                ],
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "title": "Medicines for Children leaflet: Fluticasone inhaler for asthma prevention (prophylaxis)",
                "textContent": "www.medicinesforchildren.org.uk/fluticasone-inhaler-for-asthma-prevention",
                "html": "<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/fluticasone-inhaler-for-asthma-prevention\">www.medicinesforchildren.org.uk/fluticasone-inhaler-for-asthma-prevention</xref>\n</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "specificity": {
                    "textContent": "When used by inhalation",
                    "html": "When used by <ph outputclass=\"route\">inhalation</ph>",
                    "routes": [
                        "inhalation"
                    ]
                },
                "textContent": "Patients or carers should be given advice on how to administer all fluticasone inhalations preparations.",
                "html": "<p>Patients or carers should be given advice on how to administer all fluticasone inhalations preparations.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "specificity": {
                    "textContent": "With topical use",
                    "html": "With <ph outputclass=\"route\">topical</ph> use",
                    "routes": [
                        "topical"
                    ]
                },
                "textContent": "Patients or carers should be given advice on application of fluticasone creams and ointments,",
                "html": "<p>Patients or carers should be given advice on application of fluticasone creams and ointments,</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "When used by inhalation in adults The Scottish Medicines Consortium has advised (March 2014) that fluticasone furoate/vilanterol (Relvar Ellipta ) is accepted for restricted use within NHS Scotland in patients with severe chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV1) less than 50% of the predicted normal value.",
                "html": "<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph> in adults</p> <p>The <i>Scottish Medicines Consortium</i> has advised (March 2014) that fluticasone furoate/vilanterol (<i>Relvar Ellipta</i> <tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland in patients with severe chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV<sub>1</sub>) less than 50% of the predicted normal value.</p>"
            },
            {
                "type": "smcDecisions",
                "textContent": "When used by inhalation in adults The Scottish Medicines Consortium has advised (March 2014) that Seretide 500 Accuhaler is not recommended for restricted use within NHS Scotland for chronic obstructive pulmonary disease in patients with a forced expiratory volume in 1 second (FEV1) less than 60% and greater than 50% of the predicted normal value, with significant symptoms despite regular bronchodilator therapy, and a history of repeated exacerbations.",
                "html": "<p outputclass=\"specificity\">When used by <ph outputclass=\"route\">inhalation</ph> in adults</p> <p>The <i>Scottish Medicines Consortium</i> has advised (March 2014) that <i>Seretide 500 Accuhaler</i> <tm tmtype=\"reg\"/> is <b>not</b> recommended for restricted use within NHS Scotland for chronic obstructive pulmonary disease in patients with a forced expiratory volume in 1 second (FEV<sub>1</sub>) less than 60% and greater than 50% of the predicted normal value, with significant symptoms despite regular bronchodilator therapy, and a history of repeated exacerbations.</p>"
            }
        ]
    },
    "exceptionsToLegalCategory": {
        "exceptionsToLegalCategory": [
            {
                "type": "exceptionsToLegalCategory",
                "specificity": {
                    "textContent": "With intranasal use in adults",
                    "html": "With <ph outputclass=\"route\">intranasal</ph> use in adults",
                    "patientType": "adults",
                    "routes": [
                        "intranasal"
                    ]
                },
                "textContent": "Preparations of fluticasone propionate can be sold to the public for nasal administration (other than by pressurised nasal spray) if supplied for the prevention and treatment of allergic rhinitis in adults over 18 years, subject to max. single dose of 100 micrograms per nostril, max. daily dose of 200 micrograms per nostril for max. 3 months, and a pack size of 3 mg.",
                "html": "<p>Preparations of fluticasone propionate can be sold to the public for nasal administration (other than by pressurised nasal spray) if supplied for the prevention and treatment of allergic rhinitis in adults over 18 years, subject to max. single dose of 100&#8239;micrograms per nostril, max. daily dose of 200&#8239;micrograms per nostril for max. 3 months, and a pack size of 3&#8239;mg.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76192",
                "label": "Pressurised inhalation",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76157",
                "label": "Inhalation powder",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76163",
                "label": "Nebuliser liquid",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76150",
                "label": "Cream",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76170",
                "label": "Ointment",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76199",
                "label": "Spray",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76184",
                "label": "Nasal drops",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP85605",
                "label": "FLUTICASONE WITH FORMOTEROL",
                "type": "drug"
            },
            {
                "id": "PHP85606",
                "label": "FLUTICASONE WITH SALMETEROL",
                "type": "drug"
            },
            {
                "id": "PHP85607",
                "label": "FLUTICASONE WITH VILANTEROL",
                "type": "drug"
            },
            {
                "id": "PHP88022",
                "label": "AZELASTINE WITH FLUTICASONE",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78318",
                "label": "Airways disease, use of corticosteroids",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78495",
                "label": "Nose",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_497",
                "label": "Fluticasone",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34550",
                "label": "CORTICOSTEROIDS (TOPICAL)",
                "type": "drugClass"
            },
            {
                "id": "PHP34648",
                "label": "CORTICOSTEROIDS (INTRANASAL)",
                "type": "drugClass"
            },
            {
                "id": "PHP34650",
                "label": "CORTICOSTEROIDS (INHALED)",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76192",
                "label": "Pressurised inhalation",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76157",
                "label": "Inhalation powder",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76163",
                "label": "Nebuliser liquid",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76150",
                "label": "Cream",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76170",
                "label": "Ointment",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76199",
                "label": "Spray",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76184",
                "label": "Nasal drops",
                "type": "medicinalForm"
            }
        ]
    }
}